Considering the predominant role of IL‐8–CXCR1/CXCR2 in NETosis, various clinical trials are presently underway intending to determine the efficacy of CXCR1/CXCR2 inhibitors in blocking NETs and controlling metastatic disease treatments. The gene discussed is CXCR2; the disease is metastatic neoplasm.